Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) FCF Margin (2016 - 2025)

Historic FCF Margin for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q4 2025 value amounting to 51.59%.

  • Vanda Pharmaceuticals' FCF Margin fell 477700.0% to 51.59% in Q4 2025 from the same period last year, while for Dec 2025 it was 51.1%, marking a year-over-year decrease of 429300.0%. This contributed to the annual value of 51.1% for FY2025, which is 429300.0% down from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported FCF Margin of 51.59% as of Q4 2025, which was down 477700.0% from 56.5% recorded in Q3 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' FCF Margin peaked at 50.8% during Q1 2023, and registered a low of 67.11% during Q1 2025.
  • For the 5-year period, Vanda Pharmaceuticals' FCF Margin averaged around 4.33%, with its median value being 1.39% (2022).
  • As far as peak fluctuations go, Vanda Pharmaceuticals' FCF Margin skyrocketed by 442100bps in 2023, and later plummeted by -830400bps in 2025.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' FCF Margin stood at 38.92% in 2021, then crashed by -64bps to 14.19% in 2022, then tumbled by -162bps to 8.8% in 2023, then skyrocketed by 57bps to 3.82% in 2024, then plummeted by -1251bps to 51.59% in 2025.
  • Its FCF Margin was 51.59% in Q4 2025, compared to 56.5% in Q3 2025 and 29.57% in Q2 2025.